Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)
24.30
+0.05 (0.21%)
Jul 15, 2026, 3:04 PM CST
Wuhan Hvsen Biotechnology Revenue
Wuhan Hvsen Biotechnology had revenue of 458.22M CNY in the quarter ending March 31, 2026, with 14.82% growth. This brings the company's revenue in the last twelve months to 1.74B, up 24.98% year-over-year. In the year 2025, Wuhan Hvsen Biotechnology had annual revenue of 1.68B with 40.07% growth.
Revenue (ttm)
1.74B
Revenue Growth
+24.98%
P/S Ratio
2.81
Revenue / Employee
1.54M
Employees
1,133
Market Cap
4.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.68B | 480.92M | 40.07% |
| Dec 31, 2024 | 1.20B | 180.57M | 17.71% |
| Dec 31, 2023 | 1.02B | -3.14M | -0.31% |
| Jan 1, 2023 | 1.02B | 26.68M | 2.68% |
| Jan 1, 2022 | 996.22M | 218.76M | 28.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.61B |
| Novogene | 2.26B |
| Hefei Lifeon Pharmaceutical | 1.55B |
| Kexing Biopharm | 1.46B |
| Shenzhen Weiguang Biological Products | 1.26B |
| ChemPartner PharmaTech | 1.14B |
| R&G PharmaStudies | 896.26M |
| Hangzhou Biotest Biotech | 449.50M |